Abstract: A transducer array, tumor treating field system, and method are herein disclosed. The transducer array comprises an electrode having a first side and a second side; a transfer layer covering the first side of the electrode and configured to transfer TTFields into a patient; a temperature sensor in contact with the second side of the at least one electrode; and an isolation layer covering the temperature sensor and at least a portion of the at least one electrode such that the temperature sensor is positioned between the isolation layer and the second side of the electrode, the isolation layer resisting at least one of heat flow and fluid flow through the isolation layer.

Abstract: Methods and devices for delivering therapeutic fluid to the body are described. The method may include determining a bolus delivery pattern based on a specific dietary intake of a patient and delivering the therapeutic fluid into the patient's body based, at least in part, on the determined bolus delivery pattern. The devices used in conjunction with the disclosed methods may include a controller to determine a bolus delivery pattern based on a specific dietary intake of the patient and an infusion pump to deliver the therapeutic fluid into the patient's body based, at least in part, on the determined bolus delivery pattern.

Abstract: An assembly for receiving and transmitting millimeter (mm) waves, including at least one mm wave reflector (84, 86, 88) and at least one mm transmission wave feed (72) configured in a transmission feed location (34) within the at least one mm wave reflector. The assembly also includes a plurality of receiving mm wave feeds (72) configured in respective receiving feed locations (36) within the at least one mm wave reflector; and a radio frequency (RF) module (38). The RF module is coupled to the at least one mm transmission wave feed and to the plurality of the receiving mm wave feeds, so as to drive the at least one mm transmission wave feed to transmit outgoing mm waves and to simultaneously receive incoming mm waves from all of the plurality of the receiving mm wave feeds.

Abstract: (S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate (formula (1)) or at least one active ingredient according to formula (2) for the preventive protection of people from poisoning caused by cholinesterase inhibitors.

Abstract: An assembly for receiving and transmitting millimeter (mm) waves, including at least one mm wave reflector (84, 86, 88)and at least one mm transmission wave feed (72) configured in a transmission feed location (34) within the at least one mm wave reflector. The assembly also includes a plurality of receiving mm wave feeds (72) configured in respective receiving feed locations (36) within the at least one mm wave reflector; and a radio frequency (RF) module (38). The RF module is coupled to the at least one mm transmission wave feed and to the plurality of the receiving mm wave feeds, so as to drive the at least one mm transmission wave feed to transmit outgoing mm waves and to simultaneously receive incoming mm waves from all of the plurality of the receiving mm wave feeds.

Abstract: A pharmaceutical formulation for the prophylaxis and preliminary treatment of a poisoning caused by organophosphorus cholinesterase inhibitors is characterized in that it consists of an active substance combination of at least one parasympathomimetic and at least one parasympatholytic.

Abstract: A pharmaceutical composition is disclosed comprising (-)-cis-2-methylspiro(1,3-oxathiolan-5,3')quinuclidine, and/or the pharmaceutically compatible acid addition salts thereof, together with at least one of physostigmine, tetrahydroaminoacridine, choline, lecithin, piracetam, aniracetam, pramiracetam, oxiracetam, 4-aminopyridine, 3,4-diaminopyridine, somatostatin, pirenzepine, N-methylatropine, N-butylscopolamine, scopolamine, clonidine, quanfamicine and Nerve Growth Factor. Also disclosed is a method for treating senile dementia of Alzheimer's type, which comprises coadministering to a patient in need thereof an effective dose of the spiro compound together with at least one other compound selected from those listed above.

Abstract: The (+)-cis-, (-)-cis-, (+)-trans- and (-)-trans- forms of 2-methylspiro(1,3-oxathiolan-5,3')quinuclidine are prepared by optical resolution of each of the (.+-.)-cis- and (.+-.)-trans-isomers. These compounds find application in treating diseases of the central nervous system in mammals, especially diseases due to a deficiency in the central cholinergic system. Biological tests indicate that the (-)-cis-form, as well as the (.+-.)-cis-isomer, shows particular promise for treating senile dementia of Alzheimer's type.

Abstract: Quinuclidine derivatives having the general formula (I) ##STR1## and geometrical isomers, enantiomers, diastereoisomers, racemates and/or acid addition salts thereof, wherein Z represents the group >CR.sup.1 R.sup.2 or two hydrogen atoms; and R.sup.1 and R.sup.2, which may be identical or different, are each alkyl, cyclopentyl, cyclohexyl, aryl, or diarylmethylol, or alkyl which is substituted by one or more aryl groups, or one of R.sup.1 and R.sup.2 may be hydrogen.

Abstract: There is provided a composition for the transdermal application of basic drugs which have a high specific activity. The drug is provided in combination with a fatty acid having a low molecular weight. Amongst others, the delivery system is suited for cholinergic and anticholinergic basic drugs. The compositions can be supported by a pad, bandage or the like. It is one of the advantages of the compositions of the invention that a prolonged effect can be obtained, with an essentially constant therapeutic level of the active ingredient.